Metronomic Oral Vinorelbine Combination With Tislelizumab in EGFR/ALK-negative Advanced NSCLC
Status:
ENROLLING_BY_INVITATION
Trial end date:
2025-08-07
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of metronomic chemotherapy combination with tislelizumab in EGFR/ALK-negative advanced NSCLC patients intolerant to first-line standard chemotherapy.